News & Events

BD Diagnostics, a segment of BD (Becton, Dickinson and Company), has received clearance from the U.S. Food and Drug Administration to market the BD GeneOhm™ MRSA ACP assay, a qualitative in vitro diagnostic test for the direct detection of methicillin-resistant Staphylococcus aureus (MRSA) DNA from nasal swabs in patients at risk for nasal colonization.

The BD GeneOhm™ MRSA ACP assay builds upon our already proven assay by incorporating achromopeptidase (ACP) lysis, which results in fewer assay steps and less hands-on time.Improvements delivered by this assay include:

• 15% reduction in workflow steps.

Assay concentration and centrifugation steps have been eliminated.

• 50% reduction in hands on time.

Assay concentration steps have been eliminated AND a new septum cap has been incorporated, which allows for direct sampling.

• Initial sample re-test rate of 1%.

The combination of ACP and reformulated master mix reagent reduces the number of initial sample repeats that need to be performed.

• Ability to perform follow-up testing without additional sample collection.

Sample buffer allows for follow-up testing (culture and/or PCR) without requiring a dual headed swab.

• Enhanced control features to monitor assay steps.

Control DNA are now processed through the lysis, amplication and detection steps.

For more information on the new BD GeneOhm™ MRSA ACP Assay, please contact your local HAI Specialist or customer service at 888-GENEOHM (888- 436-3646) option 1.